Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 8 (1), 576

Eltrombopag Versus Romiplostim in Treatment of Children With Persistent or Chronic Immune Thrombocytopenia: A Systematic Review Incorporating an Indirect-Comparison Meta-Analysis

Affiliations
Review

Eltrombopag Versus Romiplostim in Treatment of Children With Persistent or Chronic Immune Thrombocytopenia: A Systematic Review Incorporating an Indirect-Comparison Meta-Analysis

Jiaxing Zhang et al. Sci Rep.

Abstract

In absence of direct comparison, we conducted an indirect-comparison meta-analysis to evaluate the efficacy and safety of thrombopoietin-receptor agonists(TPO-RAs) in treatment of pediatric persistent or chronic immune thrombocytopenia(ITP). PubMed, Embase, Cochrane Library, Clinical Trials.gov, China National Knowledge Infrastructure, and Chinese Biomedical Literature Database were searched from their earliest records to May 2017. Randomized controlled trials comparing the TPO-RAs with placebo in pediatric ITP were included. Outcomes included overall response rate(primary), durable response, overall or clinically significant bleeding, the proportion of patients receiving rescue medication, and safety. Five randomized placebo-controlled studies(N = 261) were analyzed. The overall response[Risk Ratio(RR) 0.57, 95% confidence interval(CI) 0.21-1.56], the incidence of adverse events (RR 0.96, 95%CI 0.66-1.39), durable response(RR 2.48, 95%CI 0.31-19.97), and the proportion of patients receiving rescue treatment(RR 0.73, 95%CI 0.20-2.73) were similar between eltrombopag and romiplostim group. Nevertheless, eltrombopag might have lower risk of overall bleeding(RR 0.43, 95%CI 0.23-0.80) and clinically significant bleeding(RR 0.33, 95%CI 0.12-0.89) than romiplostim. This meta-analysis suggests that eltrombopag might be similar to romiplostim in efficacy and safety, but seems to reduce the risk of bleeding compared to romiplostim. Furthermore, cost of the treatment, comorbidity of patients and drug compliance should also be considered in clinical decision making.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Flow diagram of study selection process for this systematic review.
Figure 2
Figure 2
Risk of bias summary.
Figure 3
Figure 3
The efficacy results of indirect-comparison meta-analysis.
Figure 4
Figure 4
The safety results of indirect-comparison meta-analysis. URT: upper respiratory tract.

Similar articles

See all similar articles

Cited by 1 article

References

    1. Rodeghiero F, et al. Standardization of terminology, definitions and outcome criteria in an international working group immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–2393. doi: 10.1182/blood-2008-07-162503. - DOI - PubMed
    1. Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, Murata M. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol. 2011;93:329–335. doi: 10.1007/s12185-011-0791-1. - DOI - PubMed
    1. Moulis G, et al. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124:3308–3315. doi: 10.1182/blood-2014-05-578336. - DOI - PubMed
    1. Yong M, et al. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. Br J Haematol. 2010;149:855–864. doi: 10.1111/j.1365-2141.2010.08176.x. - DOI - PubMed
    1. Lee JY, et al. Epidemiology and management of primary immune thrombocytopenia: A nationwide population-based study in Korea. Thromb Res. 2017;155:86–91. doi: 10.1016/j.thromres.2017.05.010. - DOI - PubMed

MeSH terms

Feedback